Jefferies Analyst Quoting $18 After Earnings, Told Us to Buy Before Drug Approval. Read
Thomas Wei Is The Same Analysts At Jefferies That Predicted ACAD Drug Approval on March 25th and Shares Went Up $5.00 on April 11th. I provided link from March 25th Article. This is the same analyst predicting $18 after earnings report.
Article : Acadia shares rise as analyst sees drug approval
Associated Press – Mon, Mar 25, 2013 1:18 PM EDT
Jefferies analyst Thomas Wei says that overall feedback on new data from a study of pimavanserin has been positive. The analyst said Jefferies spoke with 28 neurologists about the drug at a recent conference.